Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial

Lancet

Volumn 354, Issue 9179, 1999, Pages 635-639

  Rembacken, B J ^a   Snelling, A M ^b   Hawkey, P M ^b   Chalmers, D M ^a   Axon, A T R ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GENTAMICIN; MESALAZINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STRAIN DIFFERENCE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0033592203     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)06343-0     Document Type: Article

References (33)

1. Tedesco F.J., Hardin R.D., Harper R.N., Edwards B.H. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest Endosc. 29:1983;195-197.
2. Dickinson R.J., Gilmour H.M., McClelland D.B.L. Rectal biopsy in patients presenting to an infectious disease unit with diarrhoeal disease. Gut. 20:1979;141-148.
3. Sartor R.B., Rath H.C., Sellon R.K. Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol. 12:1996;327-333.
4. hi T cells is inhibited by intestinal bacterial decontamination. Clin Immunol Immunopathol. 76:1995;S48-49.
5. Brandwein S.L., McCabe R.P., Ridwan B.U.et al. Spontaneous colitic C3H/HeJBir mice demonstrate antibody reactivity to isolated clones of enteric bacteria. Gastroenterology. 108:1995;787. abstr.
6. Taurog J.D., Richmanson J.A., Croft J.T.et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 180:1994;2359-2364.
7. Shorter R.G., Cardosa M., Remine S.J., Spencer R.J., Huizenga K.A. Modification and in vitro cytotoxicity of lymphocytes from patients with chronic ulcerative colitis or granulomatous colitis for allogenic colonic epithelial cells. Gastroenterology. 58:1970;692-698.
8. Cooke E.M. Properties of strains of Escherichia coli isolated from the faeces of patients with ulcerative colitis, patients with diarrhoea and normal persons. J Pathol Bacteriol. 95:1968;101-113.
9. Burke D.A., Axon A.T.R. Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol. 40:1987;782-786.
10. Burke D.A., Axon A.T.R. Adhesive Escherichia coli in inflammatory bowel disease and infectious diarrhoea. BMJ. 297:1988;102-104.
11. Giaffer M.H., Holdsworth C.D., Duerden B.I. Virulence properties of Escherichia coli isolated from patients with inflammatory bowel disease. Gut. 33:1992;646-650.
12. Dickinson R.J., O'Connor H.J., Pinder I., Hamilton J., Johnston D., Axon A.T.R. Double blind controlled trial of oral vancomycin in acute exacerbations of idiopathic colitis. Gut. 26:1985;1380-1384.
13. Chapman R.W., Selby W.S., Jewell D.P. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 27:1986;1210-1212.
14. Burke D.A., Axon A.T.R., Clayden S.A., Dixon M.F., Johnston D., Lacey R.W. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 4:1990;123-129.
15. Lobo A.J., Burke D.A., Sobala G.M., Axon A.T.R. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther. 7:1992;155-158.
16. Kruis W., Schütz E., Fric P., Fixa B., Judmaier G., Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 11:1997;853-858.
17. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 298:1989;82-86.
18. Truelove S.C., Witt L.J. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ. 2:1955;1041.
19. Courtney M.G., Nunes D.P., Bergin C.F.et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet. 339:1992;1279-1281.
20. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. BMJ. i:1964;89.
21. Anon. Notes for guidance on statistical principles for clinical trials: Step 4, consensus guideline. Trials to show equivalence or non-inferiority. European Agency for the Evaluation of Medicinal Products, 1998: 17.
22. Misiewicz J.J., Lennard-Jones L.E., Connell A.M. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet. i:1965;185-188.
23. Dissanayake A.S., Truelove S.C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrine). Gut. 14:1973;923-926.
24. Rijk M.C., van Lier H.J., van Tongeren J.H. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective double-blind, randomised multicenter study. Am J Gastroenterol. 87:1992;438-442.
25. Kiilerich S., Ladefoged K., Rannem T., Ranlov P.J. Prophylactic effects of olsalazine vs sulphasalazine during 12 months maintenance treatment of ulcerative colitis: Danish Olsalazine Study Group. Gut. 33:1992;252-255.
26. Giaffer H., Holdsworth C.D., Lennard-Jones J.E.et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther. 6:1992;479-485.
27. Riley S.A., Mani V., Goodman M.J., Herd M.E., Dutt S., Turnberg L.A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 94:1988;1383-1389.
28. Sutherland L., Roth D., Beck P., May G., Makiyama K. The use of oral 5-aminosalicylic acid for maintenance of remission of ulcerative colitis. In: Cochrane Library [CDROM and Online]. Cochrane Collaboration, issue 3. Oxford: Update Software, 1998.
29. Fockens F., Mulder C.J., Tytgat G.N.et al. Comparison of efficacy and safety of 1·5 compared with 3·0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol. 7:1995;1025-1030.
30. Sutherland L.R., May G.R., Shaffer E.A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 118:1993;540-549.
31. Riley S.A. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut. 42:1998;761-763.
32. Bennet J.D., Brinkman M. Treatment of ulcerative colitis with implantation of normal colonic flora. Lancet. i:1989;164.
33. Blum G., Marre R., Hacker J. Properties of Escherichia coli strains of serotype O6. Infection. 23:1995;234-236.